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Drug-induced liver injury (DILI) remains a leading cause for the withdrawal of approved
drugs. This has significant financial implications for pharmaceutical companies, places
increasing strain on global health services, and causes harm to patients. For these
reasons, it is essential that in-vitro liver models are capable of detecting DILI-positive
compounds and their underlying mechanisms, prior to their approval and administration
to patients or volunteers in clinical trials. Metabolism-dependent DILI is an important
mechanism of drug-induced toxicity, which often involves the CYP450 family of enzymes,
and is associated with the production of a chemically reactivemetabolite and/or inefficient
removal and accumulation of potentially toxic compounds. Unfortunately, many of the
traditional in-vitro liver models fall short of their in-vivo counterparts, failing to recapitulate
the mature hepatocyte phenotype, becoming metabolically incompetent, and lacking the
longevity to investigate and detect metabolism-dependent DILI and those associated
with chronic and repeat dosing regimens. Nevertheless, evidence is gathering to indicate
that growing cells in 3D formats can increase the complexity of thesemodels, promoting a
moremature-hepatocyte phenotype and increasing their longevity, in vitro. This reviewwill
discuss the use of 3D in vitromodels, namely spheroids, organoids, and perfusion-based
systems to establish suitable liver models to investigate metabolism-dependent DILI.
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INTRODUCTION
Drug-induced liver injury (DILI) is associated with a large proportion of withdrawn drugs (1) and
is a leading cause of acute liver failure (2). This puts considerable strain on global health services
and can have significant financial implications for pharmaceutical companies. Understanding the
mechanisms that underlie DILI, therefore, remains an ongoing challenge in pharmacology and
toxicology research. DILI may be associated with immunological reactions, diet-drug or drug-
drug interactions, genetic variation in drug metabolizing enzymes and transporters (DMETs), or
any combination of these factors (3, 4). This makes them extremely difficult to investigate, and,
unfortunately, there is no perfect model system to study DILI, with different models varying in their
complexity, relevance, cost, and ethical acceptance. Although in-vivo animal studies are necessary
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for getting a drug’s approval, their use is a contentious area and
the translatability of animal data to humans can also be low
(5, 6). Hence, developing new in-vitromodels that utilize human-
derived cells provides a more ethically acceptable alternative that
may be more translatable. Although there have been a number
of comprehensive reviews on the different in-vitro liver models
that can be used to evaluate a drug’s toxicity and study DILI
(7–12), this review will discuss the use of human-based cells to
establish in-vitro models to study metabolism-dependent DILI,
including the metabolic capabilities of 3D cultures, co-cultures,
and perfusion-based platforms.
THE ROLE OF THE LIVER
The liver provides the primary route for compounds to enter the
systemic circulation from the gastrointestinal tract. It has high
metabolic capabilities to metabolize and modify these incoming
compounds, a process known as first pass metabolism, and
provides a major route for elimination via bile canaliculi and the
bile ducts. The human liver consists of two lobes that contain
functional units or lobules called “hepatic acini.” Each of these
units is hexagonal in shape and has a portal triad at each corner
around its periphery (13). Each portal triad includes a branch
of the hepatic portal vein, a branch of the hepatic artery, and
a branch of the biliary tree. At the center of each lobule is the
FIGURE 1 | The functional unit or lobule of the liver (aka. The hepatic acinus). At each corner of each lobule is a portal triad, which contains branches of the hepatic
portal vein, hepatic artery, and biliary tree. At the center of each lobule is the centrilobular vein. The lobule has an oxygen concentration gradient across it, with zone 1
having the highest concentration and zone 3 the lowest.
centrilobular vein (Figure 1). Sinusoids (i.e., capillaries with large
permeable pores) connect the portal triad veins and arteries to the
centrilobular vein (13). Oxygenated blood flows from the hepatic
artery into the sinusoids where it mixes with nutrient-rich blood
delivered from the small intestine via the hepatic portal vein
(Figure 2). The highly porous sinusoidal endothelium ensures
that the oxygen- and nutrient-rich blood can highly perfuse the
surrounding hepatocytes as it flows to the centrilobular vein
and enters the systemic circulation. As the oxygen is utilized
by these hepatocytes, it creates an [O2] gradient across the
lobule (i.e., from the periphery to the center). This enables each
lobule to be split into 3 zones based on the O2 concentration,
with hepatocytes in each zone having zone-specific functionality
(Figure 1) (14).
Hepatocytes are the parenchymal cells of the liver and account
for 60% of all liver cells (7). Differential expression of transporters
between the basolateral and apical membranes ensures they
are suitably equipped to uptake and efflux compounds from
and into the blood and eliminate those destined for biliary
excretion (e.g., toxic metabolites, bile acids, and bilirubin—
the potentially toxic by-product of haem degradation) (15,
16). Alongside biliary excretion, hepatocytes have several other
important functions, including (1) detoxification of ammonia via
the urea cycle, (2) energy storage in the form of glycogen, (3)
production of energy yielding precursors (i.e., pyruvate, glucose,
and acetyl-CoA) via glycogenolysis, the Cori cycle, amino acid
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FIGURE 2 | Microanatomy of the hepatic lobule. Oxygenated blood and nutrient-rich blood enter the sinusoid from the hepatic artery and portal vein, respectively,
which flows to the center of the lobule where it enters the systemic circulation via the centrilobular vein. Sinusoidal endothelial cells line the sinusoid, which is
surrounded by hepatocytes. Kupffer cells reside along the sinusoidal wall, removing any foreign particles, whilst stellate cells are localized in the space of Disse and act
as storage cells for vitamin A.
metabolism, beta-oxidation, and gluconeogenesis, (4) synthesis
of cholesterol, bile acids, and ketone bodies, (5) lipoprotein
metabolism, and (6) synthesis and secretion of serum proteins
(e.g., albumin and coagulation factors). However, as stated, the
function of a specific hepatocyte will be dependent on its location
in the lobule (i.e., its zone). For example, zone 1/periportal
hepatocytes tend to be specialized toward cholesterol synthesis,
fatty acid oxidation, dehydrogenase-mediated oxygenation,
sulfonation, and gluconeogenesis; whereas, zone 3 are specialized
toward bile acid synthesis, glutamine synthesis, lipogenesis,
CYP450-mediated oxidation, glucuronidation, and glutathione
conjugation (14, 17).
Non-parenchymal cells (NPCs) make up the remaining 40%
of cells in the liver and include the sinusoidal endothelial cells,
stellate cells, Kupffer cells, and cholangiocytes (7). Sinusoidal
endothelial cells form the leaky capillaries throughout the liver,
enabling high perfusion of hepatocytes with plasma. Dispersed
throughout the sinusoidal endothelium, Kupffer cells reside
as liver macrophages that continually survey the circulating
blood for foreign pathogens/ particles. They can act as antigen
presenting cells to activate the adaptive immune response
and play an important role in the inflammatory response,
removing compromised cells and secreting pro-inflammatory
cytokines (18, 19). They also remove damaged red blood cells
and those at the end of their life, breaking down haem into
bilirubin, ready for its removal by hepatocytes (18). Stellate
cells represent 5–8% of cells in the liver and are located in
the space of Disse, between the sinusoidal endothelial cells
and hepatocytes (Figure 2). They store lipid-soluble vitamins
such as vitamin A and play a part in regulating blood flow.
Importantly, during liver injury and inflammation, stellate
cells can reduce their lipid content and transdifferentiate into
α-smooth muscle actin (α-SMA) positive myofibroblast-like
cells, which deposit large amounts of extra cellular matrix
(ECM) and secrete pro-inflammatory cytokines, creating a pro-
inflammatory and pro-fibrogenic environment (20). Although
part of the wound-healing process, excessive remodeling of
the liver ECM and loss of parenchymal liver cells can lead
to the development of scar tissue, liver fibrosis, regenerative
nodules, which, as the liver loses its functional capacity,
can progress to liver cirrhosis and liver failure (21, 22).
Cholangiocytes are epithelial cells that line the biliary duct
and facilitate biliary excretion by modifying the bile pH,
its composition, volume, and permitting the re-uptake of
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FIGURE 3 | Overview of Phase I, II, and III reactions for xenobiotic metabolism and excretion. CYP450, cytochrome P450; FMO, flavin monooxygenases; AKR,
aldo-keto reductases; DH, dehydrogenases; UGT, UDP-glucuronyl transferase; SULT, sulfotransferase; GST, glutathione-S-transferase; NAT, N-acetyl transferase;
AAT, amino acid transferase; ABC, ATP-binding cassette.
components from the bile (e.g., glucose, amino acids, and ions)
(23, 24).
METABOLISM AND DRUG-INDUCED
LIVER INJURY
Due to the liver’s role in first pass metabolism, detoxification,
and elimination of compounds, it can be exposed to high
concentrations of drugs and their metabolites. It is, therefore,
especially vulnerable to drug-induced injuries associated with
genetic variation in drug metabolizing enzymes and transporters
(DMETs) or perturbation of their function (e.g., induction
or inhibition). Metabolism and detoxification of xenobiotics
typically consists of three phases (i.e., phase I–III), and the
expression of many of these proteins is regulated by several
nuclear receptors. Functionalization of xenobiotics is carried out
in phase I metabolism and involves the addition or exposure
of functional groups to permit their conjugation to polar
compounds in phase II metabolism. The resulting conjugates
are generally more water-soluble, charged at physiological pH,
and thus better substrates for phase III transporters, enabling
hepatic excretion into the bile (Figure 3). CYP450 enzymes
play an important role in phase I metabolism of lipophilic
compounds, with CYP1, CYP2, and CYP3 families metabolizing
70 to 80% of approved drugs (25). Although CYP450-
mediated metabolism is an important pathway for detoxifying
many drugs and their toxic metabolites, it can also generate
reactive metabolites that can react with and disrupt cellular
macromolecules (e.g., lipid membranes and proteins), resulting
in hepatocyte toxicity (26). In fact, the DILI risk for a drug
is considerably higher if it is a CYP450 substrate (27). Flavin-
containing monooxygenases (FMOs), although contributing to
a much lesser extent than CYP450 enzymes, also contribute
to the phase I metabolism of many drugs, with FMO3 being
the most abundant isoform in the adult human liver (28,
29). Other families involved in phase I metabolism include
aldo-keto reductases, monoamine oxygenases, esterases, epoxide
hydrolases, and alcohol/aldehyde dehydrogenases (30). Phase II
reactions involve the conjugation of xenobiotics with glucuronic
acid, amino acids (i.e., glycine or taurine), a sulfonate group, an
acetyl group, a methyl group, or glutathione via glucuronidation,
amino acid conjugation, sulfonation, N-acetylation, methylation,
and glutathione conjugation, respectively (31). Proteins involved
in phase III metabolism include members of the ATP-binding
cassette (ABC) transporter family such as MRP2 (ABCC2), BSEP
(ABCB11), and P-glycoprotein (ABCB1). Drugs that inhibit these
transporters, especially BSEP, have an increased risk for causing
DILI (32). Importantly, many of these DMETs are also highly
polymorphic, with some individuals having gene variants that
Frontiers in Medical Technology | www.frontiersin.org 4 November 2020 | Volume 2 | Article 611913
Cox et al. 3D Liver Models
TABLE 1 | Examples of drugs that can cause DILI, the drug metabolizing enzymes and transporters implicated in their toxicity, and the proposed mechanism(s).
Drug (Class) Toxicity Implicated
DMETs
Mechanism References
Acetaminophen
(Analgesic)
Hepatotoxicity CYP2E1 ↑ NAPQI → ↑ Protein Adducts (33)
Isoniazid
(Anti-tuberculosis)
Hepatotoxicity CYP2E1, NAT2,
GSTM1
Mechanism unclear and controversial (↑ reactive
metabolite(s) → ↑ protein adducts?)
(34–38)
Diclofenac
(Analgesic)
Hepatotoxicity UGT2B7,
CYP2C8, ABCC2
↓ Glucuronidation → ↑ quinonimines → ↑ cell
stress
(39, 40)
Ticlopidine
(Anti-platelet)
Hepatotoxicity CYP2B6 and HLA Mechanism unclear (immune mechanism?) (41)
Tolcapone
(Anti-Parkinson)
Hepatotoxicity UGT1A Mechanism unclear (↓ glucuronidation → ↑
tolcapone → ↑ mitochondrial toxicity?)
(42)
Troglitazone
(Anti-diabetic)
Hepatotoxicity/Cholestasis CYP3A4?,
SULT1A3?, UGT?
Mechanisms unclear and controversial
1) ↑ TGZ-sulfate → ↑ BSEP inhibition → ↑
intracellular bile acids → Cholestasis
→ Mitochondrial toxicity → apoptosis
2) ↑ TGZ → direct mitochondrial toxicity
3) ↑TGZ-quinone → ↑ reactive intermediates (e.g.,
TGZ-epoxide, open-ringed metabolite, or
superoxide anion radical) → ↑ protein adducts,
oxidative stress, mitochondrial toxicity
(43–45)
Fialuridine (Antiviral) Hepatotoxicity ENT1 Fialuridine is transported into mitochondria by
ENT1 → metabolized to its triphosphate derivative
→ inhibits polymerase-gamma → mitochondrial
depletion → lactic acidosis and liver failure
(46, 47)
Bosentan
(Anti-hypertensive)
Cholestatic BSEP BSEP inhibition → ↑ intracellular bile acids
→ cholestasis
(48, 49)
cause loss-of function (poor metabolizers) or gain-of function
(extensive metabolizers). This can cause over production or
inefficient removal of a drug or its metabolite, resulting in its
accumulation to cytotoxic concentrations that lead to DILI.
There are now a number of examples of how genetic variation
in DMETs or perturbation of their function (e.g., induction
or inhibition of DMETs by drugs, foods, or disease states)
can predispose an individual to DILI, including isoniazid and
diclofenac (Table 1).
The metabolic heterogeneity for hepatocytes across each
liver lobule can also result in zone-specific toxicities. For
example, drug-induced toxicities that are associated with CYP450
activation may become more apparent at the centrilobular
region of the liver (i.e., zone 3) at lower concentrations, due
to higher CYP450 activity in these hepatocytes. Likewise, drugs
activated by dehydrogenases may become more apparent at
periportal hepatocytes (i.e., zone 1). Classic examples of this
include the hepatotoxic compounds carbon tetrachloride and
allyl alcohol, which cause centrilobular and periportal toxicity,
respectively (50). Hence, certain toxicities may only be detectable
at physiologically relevant concentrations in models that can
sufficiently recapitulate a specific zone of the liver.
After identifying the gene polymorphisms that predispose an
individual to developing hepatotoxicity, patients can be stratified
into low- and high-risk groups for developing DILI based on
their genetics. This allows a personalized medicine approach
to prescribing, with high-risk patients being given a modified
dose or, if possible, a safer alternative. Unfortunately, the exact
gene variant responsible for a person developing DILI is often
unknown and may be difficult to identify due to the relatively
rare incidence of DILI, gene-gene interactions, and environment-
gene interactions.
The complexity of the liver severely complicates the
development of a single in-vitro model capable of modeling
all the desired features. To be able to detect DILI with a
metabolic basis, in-vitromodels must bemetabolically competent
(i.e., expressing the aforementioned DMETs to sufficient
concentrations), display hepatocyte functionality, and, ideally,
be patient specific. It is also clear that drug-induced toxicities
may be mediated by, or involve, multiple cell types (e.g., non-
parenchymal cells such as fibroblasts, stellate cells, Kupffer cells),
and thus may require co-culture model systems to detect (7).
Moreover, the ideal model system to studyDILI should have good
sensitivity and specificity to detect DILI-positive compounds,
indicating that the adverse outcome pathway is present within
that system.
ESTABLISHING IN VITRO LIVER MODELS
USING HUMAN-BASED CELLS
The complexity of in-vitro liver models that utilize human-
based cells can range from simpler monoculture models, which
include a single cell type, to those with two or more cell types
(i.e., cocultures and organoids). Importantly, the model should
be able to recapitulate some functional aspect of the cells or
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organ that you are trying to model. Being the parenchymal
cell of the liver, hepatocytes are a critical component for
establishing an appropriate liver model, and in the case of
metabolism-dependent DILI, they need to be metabolically
competent for hepatocyte-specific DMETs. Currently, human-
derived hepatocytes that are used for establishing these models
are derived frommultiple sources. These include primary human
hepatocytes (PHHs), which are derived from liver patients
that have undergone liver resection or biopsy (51, 52); cancer
cell lines, which have been isolated from liver tumors (53–
55); immortalized cell lines, which are hepatocytes that have
undergone genetic modification to prevent cell death and
promote survival (56, 57), and hepatocyte-like cells (HLCs),
which are derived from pluripotent or adult stem cells (58–
61). Each cell type has its own advantages and disadvantages
(discussed throughout), but when they are grown in vitro,
they will often be phenotypically different from their in-vivo
counterparts for which you are trying to make conclusions (62–
66). To try to overcome these phenotypic differences, a number of
techniques have been used to try to recapitulate the hepatocyte’s
native environment in vitro, and evidence is gathering to suggest
that growing cells in 3D (67–74) or exposing them to shear
stresses and flow (75–77) can promote a more physiologically
relevant model to study DILI, based on hepatocyte function and
metabolic capabilities.
Other cell types used in combination with hepatocytes to
establish in-vitro liver models include the non-parenchymal cell
types found in the liver (i.e., Kupffer cells, stellate cells, liver
sinusoidal endothelial cells (LSECs), and cholangiocytes), with
the aim of recapitulating the liver’s multi-cellular environment
and paracrine signaling. Similar to PHHs, NPCs can be primary
human cells derived from liver resection/biopsies (e.g., NPC
liver fractions or isolated Kupffer cells) (32, 68, 78–81). Cancer/
immortalized cell lines can also be used to represent the
liver-specific NPCs (82). For example, THP1 cells (a human
acute monocytic leukemia cell line) and hTERT-HSCs (an
immortalized human stellate cell line) have been used as Kupffer
cell and stellate cell surrogates, respectively (82). Endothelial cells
and mesenchymal stem cells are also being used in combination
with hepatocytes to try to emulate the endodermal, endothelial,
and mesenchymal interactions that occur during organogenesis
and liver bud formation (83), with human umbilical vein
endothelial cells (HUVECs) being used (83, 84) or endothelial
cells derived from pluripotent stem cells (72, 85). Importantly,
data indicates that the addition of these different cell types
can promote hepatocyte maturation and metabolic competence
in vitro (32, 68, 71, 72, 78–80, 82–86) and, therefore, may be
important for detecting some mechanisms of DILI.
3D CULTURES
There is growing evidence indicating that culturing cells in
3D can promote a more in vivo-like phenotype than the same
cell type cultured in 2D, when considering hepatocyte function
and expression of DMETs (69, 71, 87–90). Consequently,
they show greater sensitivity to detect toxicity for known
hepatotoxic compounds, when compared to 2D cultures (12,
69, 81, 87). Another major benefit of growing cells in 3D
is the ability to culture cells for longer, enabling longer and
repeat dosing regimens that more closely resemble those seen
in the clinic, which in turn allows the detection of previously
undetectable chronic toxicities (e.g., fialuridine) (47, 68, 71).
Three-dimensional in-vitro liver models include spheroids,
organoids, and perfusion-based platforms, which can be further
classified by their size, the presence and composition of a scaffold,
and the technique used to form the cell aggregates (Figure 4),
discussed below.
Organoids or Spheroids?
Liver spheroids and organoids have the benefit that cells are
grown as 3D structures, allowing the development of cell-cell
interactions, similar to that seen in their in-vivo environment.
Data indicates that this can help promote a more mature
hepatocyte phenotype in vitro (74, 91). Although the meaning
of the term organoid has evolved over time, it can typically be
defined as a self-organizing 3D structure, which includes multiple
cell types, and is derived from pluripotent stem cells (83, 85)
or tissue-resident cells isolated from biopsies (92–94), and can
recapitulate in some way the structure and function of a specific
organ (95, 96). Organoids form in response to chemical cues and
cell-cell interactions that follow the developmental time course
for that organ (96, 97). The morphology of liver organoids can
vary from cyst-like structures (Figure 5A) (92) to more dense
structures (83, 94) depending on the initial cell type(s) used
to form the organoid. In contrast, spheroids are aggregates of
cells that typically form a solid spheroidal structure (Figure 5B),
which can include one or more cell types and can recapitulate
some functional aspect(s) of an organ. Organoids and spheroids
that contain multiple cell types (i.e., cocultures) are typically
considered to have more physiological relevance, due to being
able to recapitulate the multi-cellular environment that occurs
in-vivo, and data suggests this can promote a more mature
hepatocyte phenotype (see Co-cultures and Organoids sections).
Certain toxicities may also involve multiple cell types, and,
therefore, may only become detectable in these heterogenous
models. However, due to the increase in complexity and the
contribution of multiple cell types to the parameters of interest,
data analysis and interpretation can become more challenging.
Monoculture spheroids, in contrast, have the advantage of being
able to do single cell-type analysis without the use of techniques
such as fluorescence-activated cell sorting (FACS) to separate
cells into their constitutive parts, enabling non-confounding
metabolic analysis.
Self-Assembly or Scaffold Systems?
Although some cell types can form 3D structures without any
scaffold or matrix present, others may need a solid support
system in order to form. As the name suggests, scaffold-
dependent methods to produce 3D cultures relies upon a
synthetic or biological scaffold or matrix to grow cells in a 3D
format. The use of such scaffolds can also help cells establish a 3D
structure with a particular architectural arrangement, which can
now be achieved with extraordinary precision using bioprinting
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FIGURE 4 | Overview of the different 3D models and methods used to produce them.
techniques (98). Biological scaffolds can also help to recapitulate
the cell’s in-vivo environment by including interactions between
cells and the extracellular matrix (ECM) and mimicking the
mechanical forces inflicted on cells (e.g., matrix stiffness), which
can play an important role in cellular signaling, cellular behavior,
and cell fate (99, 100). When using scaffolds, however, it
is important to understand the effect that the scaffold has
on cellular phenotype, any toxicity associated with the use
of synthetic materials, and the extent of binding between
drugs/proteins/compounds and the scaffold. Scaffolds can vary
from decellularized liver tissue (101) to semi-synthetic (102) or
fully synthetic constructs (103). Fully synthetic scaffolds have the
advantage of being more reproducible, whereas decellularized
liver tissue can retain the original architecture of the in-vivo
liver. In contrast, scaffold-free methods rely upon self-assembly
of cells into a 3D structure that permits the formation of cell-cell
interactions. The methods used to produce such cultures include
the hanging drop method (104), liquid overlay technique (69),
the use of ultra-low adhesion plates (71), or rotating bioreactors
(105) (Figure 4).
Longevity
The ability to culture and dose cells for longer is an important
advantage of 3D spheroids, when compared to 2D monolayers;
however, the longevity of these model systems is limited by
the development of a hypoxic and necrotic core or loss of
hepatocyte function. Development of a necrotic core, however,
is size-dependent and, therefore, typically associated with 3D
spheroids formed with proliferating cells, which become larger
over time, limiting the diffusion of oxygen into its core. This
can be avoided by using mature, non-proliferating cells. The
diameter at which hypoxia becomes apparent is often quoted to
be 400µm (106), but this will vary across cell types and should
be determined experimentally, as different cell types will have
different oxygen consumption rates, some of which have been
modeled in silico (107, 108). Several studies indicate that 3D
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FIGURE 5 | (A) Phase contrast image showing the cyst-like morphology of liver organoids derived from bipotent EPCAM+ biliary cells (Top image) and
immunofluorescent image showing a layer of hepatocytes around the organoid’s periphery; blue (Hoechst) = nuclei; green (Anti-E-cadherin antibody) = E-cadherin,
the epithelial marker for hepatocytes (Bottom image). (B) Phase contrast image showing the dense morphology or HepG2 spheroids (Top image) and Haematoxylin
and Eosin stained cross-sections of two HepG2 spheroids (Bottom image). Scale bars are 100µm.
spheroids can be maintained for at least 1 month, following
optimisation for cell seeding number (67–69), with reports of
iPSC-derived hepatocyte-like cell spheroids being functional for
up to 365 days (109). The number of proliferating cells within
spheroids also tends to decrease over time, with proliferating cells
becoming localized to the periphery when using proliferating
cell types, which may be due to limited diffusion of oxygen
and nutrients into deeper regions of the spheroid and inefficient
removal of waste products, which together cause cells to become
quiescent (10). Data also indicates that cells at the spheroid’s core
may develop a mesenchymal phenotype (i.e., undergo epithelial-
mesenchymal transition), although they are yet to be fully
characterized (109).
Dosing Window
Selecting the correct time point for dosing or carrying out
experiments may also be important for a specific toxicological
study, as data indicates that expression of albumin and a number
of important DMETs increases over time for HepG2 spheroids,
with some only beginning to increase after 7 or 14 days in culture
(67). The addition of non-parenchymal cells to cultures can also
promote the expression of hepatocyte markers in 3D cultures
and promote organoid maturation (84). Although both paracrine
signaling and cell-cell interactions promote these changes, the
3D organization of organoids seems to be dependent on cell-cell
interactions between parenchymal cells and non-parenchymal
cells (84).
IMMORTALIZED/CANCER CELL LINES
Many of the current in-vitro liver models involve the use of
immortalized or cancer-derived cell lines, and although these
models are robust, reproducible, and relatively cheap, the cells
used are often phenotypically different from in-vivo hepatocytes
(62). These cell lines tend to have abnormal chromosome
numbers, chromosome abnormalities, and oncogenic mutations
that promote survival (110–114), and thus may be more suitable
to model cancer than drug-induced liver injury. Their ability to
detect drug-induced liver injury is also limited, as many fail to
express important enzymes involved in xenobiotic metabolism
(115) and they lack the genetic variability to study patient-
specific adverse drug reactions. Protein expression also varies
considerably across cell lines (62, 116), as does their response to
drugs (117), so choosing themost appropriate cell line is no trivial
process and will be dependent on the question(s) of interest.
Commonly used cancer-derived cell lines include HepG2,
HepG2/C3A, Huh7, and HepaRG. Although phenotypically
different from healthy in-vivo hepatocytes, studies indicate that
growing these cells in 3D can promote a more mature phenotype
than the same cells cultured as 2D monolayers or sandwich
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cultures, based on hepatocyte function and expression of DMETs
(Table 2).
HepG2
HepG2 cells have been shown to maintain certain hepatic
functions, including secretion of A1AT, albumin, α1-acid
glycoprotein, AFP, transferrin, lipoprotein, complement proteins,
fibrinogen and plasminogen (53). However, proteomic analysis
indicates that they more closely resemble fetal hepatocytes
than adult hepatocytes (64). Thanks to inducible CYP1A1,
HepG2 cells have previously been used to detect mutagens
activated by this enzyme (128, 129). Unfortunately, due to low
or undetectable expression for a number of other enzymes
involved in drug metabolism (i.e., CYP2E1, CYP3A4, CYP2C9,
CYP2C19, CYP7A1, UGT1A, NAT2, and ABCB11), their ability
to investigate DILI with a metabolic basis is limited (62, 128).
There are, however, examples of transfected HepG2 cell lines that
express different CYP450 enzymes, making them better able to
detect metabolism-mediated hepatotoxicity (130–132).
Data indicates that culturing HepG2 cells in 3D can increase
expression of a number of DMETs (67) and promote the
correct localization and function of nuclear receptors, CAR (127)
and PXR (126). Spheroids also have higher levels of albumin
secretion, when compared to 2D monolayers (104, 105, 123–
125), although there is some contradictory data (120). Albumin
secretion may also be influenced by spheroid size, with larger
spheroids showing less secretion (123). Whether this is due to
diffusion limitations remains to be determined. Growing HepG2
as spheroids can also influence the regulation of CYP1A, with
the aryl hydrocarbon receptor (AhR) only regulating CYP1A1
in spheroids, whereas it regulates both CYP1A1 and CYP1A2
in 2D monolayer cultures (122). The difference in regulation
for CYP1A2 seems to involve PXR and may also be cell line
specific (122).
HepaRG
HepaRG is a bipotent progenitor cell line derived from a
human hepatoma, which is capable of differentiating into a
mixed population of hepatocyte- and cholangiocyte-like cells
when treated with dimethyl sulfoxide (DMSO) (55, 133). When
comparing different cell lines cultured as 2D monolayers,
HepaRG show higher expression for a number of important
DMETs, more closely resembling PHHs (Figure 6) (63, 89,
116). They also express inducible CYP450 enzymes, including
CYP3A4, which, following induction, is comparable to basal
expression and activity in freshly isolated PHH (63). In fact,
HepaRG 2D monolayer cultures were shown to be superior to
HepG2 3D cultures, when comparing DMET expression (134).
When HepaRG are cultured as 3D spheroids, the expression
of a number of genes involved in gluconeogenesis, glycolysis,
energetic lipid synthesis, bile acid metabolism, and lipoprotein
metabolism increase in a time-dependent manner, and the
expression of many of these was significantly higher than
in 2D HepaRG cultures (104). A similar trend was seen for
a number of phase I, II, and III proteins (88). However,
TABLE 2 | Comparison of cancer-derived cell lines grown in 3D with those grown
in 2D monolayers.
Cell
Type
Finding (3D vs. 2D) Reference(s)
C3A Increased albumin secretion in 3D spheroids (69, 118)
Increased CYP2E1 protein expression in 3D
spheroids
Increase in CYP1A2 and CYP3A4 activity in 3D
spheroids
(118)
Urea secretion and CYP3A4 protein expression
comparable in 2D and 3D spheroids
Increased CYP1A2 protein expression in 3D
spheroids
Increased urea secretion in 3D spheroid (69)
3D spheroids develop bile-canaliculi-like structures
3D spheroids have increased sensitivity to detect
some hepatotoxins
HepaRG Increased urea secretion in 3D spheroids (73)
Higher CYP2B6 activity in spheroids
CYP3A4 and CYP1A2 activity comparable in 3D
and 2D cultures after 7 days
Increased albumin secretion in 3D spheroids, which
increases over time in culture
(104, 119)
Increased ApoB secretion in 3D spheroids (104)
Albumin secretion comparable between 3D
spheroids and 2D monolayer
(88)
Sensitivity to APAP, ketoconazole and
chlorpromazine toxicity was comparable in 2D
monolayers and 3D spheroids
Increased CYP1A2, CYP2B6 and CYP3A4 activity
in 3D spheroids and more inducible
(70, 88)
HepG2 3D spheroids have increased expression for genes
involved in metabolism and synthesis, whereas 2D
spheroids have increased expression for ECM,
adhesion and proliferation genes
(105)
Decreased albumin secretion in 3D spheroids (120)
GSTO1, GSTT1, and glutathione synthetase protein
expression lower in 3D spheroids
(90)
More variation in protein expression data for 3D
spheroids than for 2D monolayers
Increased CYP1A expression, activity and/or
induction in 3D spheroids
(105, 121–124)
Higher expression of nuclear receptors in 3D (67)
Increased CYP2E1 expression in 3D spheroids but
lower CYP2E1 activity
Higher UGT and SULT activity in 3D spheroids
3D spheroids develop bile-canaliculi-like structures
Increased activity for CYP2C9, 3A4 and 2D6 in 3D
spheroids
Increased albumin secretion in 3D spheroids (104, 105, 121,
123–125)
Increased ApoB secretion in 3D spheroids (104)
CAR and PXR functional in 3D spheroids but not 2D
monolayers
(126, 127)
Huh7 PXR functional in 3D spheroids but not 2D
monolayers
(126)
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FIGURE 6 | Heatmap comparing the expression for a number of proteins involved in xenobiotic metabolism and liver function. Expression data is for 2D monolayers:
HepG2 relative to primary human hepatocytes (PHHs), HepaRG relative to PHHs, and HepaRG relative to HepG2. Data is reported as log2 of relative expression and
sourced from a previously published study (116).
contradictory data is seen for CYP3A4 activity, with some
studies showing higher activity in 3D spheroids (70, 119) and
another showing comparable activity (73). Comparable activity
was seen for CYP1A2 with 2D monolayers and 3D spheroids
(70, 73), although another study reported significantly higher
CYP1A activity (i.e., using EROD assay) (119). CYP2B6 activity
was shown to be higher for 3D spheroids (70, 73). HepaRG
spheroids display inducible CYP450 enzymes in response to
known pharmacological inducers, indicating functional nuclear
receptors (i.e., PXR, CAR, and AhR) (70, 88, 104, 119). They
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also have glycogen synthesis and storage capabilities and develop
bile-canaliculi-like structures (70), and have been shown to
maintain viability for at least 21 (73) and 28 days (70). The
superior DMET profile for HepaRG spheroids and the ability
to repeat dose them over several day or weeks increases their
sensitivity to detect hepatotoxicity for some known hepatotoxic
drugs (70, 73, 119). They may also be able to better detect
genotoxicity than 2D cultures (135). Due to being terminally
differentiated cells, HepaRG spheroids are less likely to suffer
issues with a hypoxic core, which can be problematic when using
continually proliferating cell lines such as HepG2. However, due
to the time required to grow and differentiate these cells, the
high cost, and the loss of proliferation following differentiation,
HepaRG are less amenable to high throughput analyses. The
mixed population of biliary-like epithelial cells and hepatocytes
following differentiation may help reveal mechanisms of toxicity
involving both cell types, but in some cases couldmake themodel
more complex without adding much mechanistic benefit.
PRIMARY HUMAN HEPATOCYTES
Due to being patient-specific and having sufficient expression
of hepatocyte-specific genes upon isolation, primary human
hepatocytes (PHHs) and liver tissue remain the “gold standard”
for investigating drug-induced liver injury and patient-specific
toxicities (8). Unfortunately, these can be of limited availability,
require invasive procedures to source, and undergo rapid
dedifferentiation when cultured in vitro, with reduced DMET
expression occurring within 48 h of plating (66, 74, 136–
138) and considerable transcriptomic changes detected as early
as 30min after plating (138). Data indicates that during
this dedifferentiation process, cells acquire a regenerative-
like phenotype with reduced activity for transcription factors
involved in hepatocyte differentiation (e.g., HNF4 and HNF1a)
and increased activity for those involved in stemness and
proliferation (e.g., MYC), resembling that seen following
partial hepatectomy (74). Importantly, unlike PHHs cultured
as 2D monolayers, those cultured as 3D spheroids reacquire
a phenotype indicative of a redifferentiation-like process (i.e.,
recovery of DMET expression—discussed below), following
spheroid formation and re-establishment of cell-to-cell contacts,
providing evidence for the importance of cell-cell interactions
in PHH dedifferentiation and maintenance of the mature
hepatocyte phenotype (74). Unlike the in-vivo regenerative
process, however, the cells in 3D spheroids fail to proliferate
to any appreciable level, which may be due to reduced Wnt/
beta-catenin signaling, leading to increased p53 activity and
expression of PAI-1 (aka. Serpine1) (74), the latter of which
has been associated with induction of replicative senescence
(139). As well as loss of cell-to-cell contacts, several other factors
associated with the isolation of PHHs have been implicated
in the dedifferentiation process, including ischemia-reperfusion
phenomenon, induction of an inflammatory response, and loss
of cell-to-ECM interactions (136). Changes to the mechanical
forces inflicted on PHHs when plated onto stiff substrates may
also influence the hepatocyte phenotype (140).
When PHHs are cultured as 3D spheroids, the downregulation
of ADME proteins is much less than in 2D monolayers (71).
CYP1A2, CYP2C8, and CYP3A4 activity is also higher in PHH
spheroids, with CYP2C9 and 2D6 activity being maintained for
longer than in 2D sandwich cultures and monolayers (tested
over 14 and 21 days) (71, 141). In fact, data indicates that
PHH spheroids remain viable and metabolically competent,
maintaining activity for CYP1A1, 2D6, and 3A4, for at least 35
days (68). CYP2C9 activity tends to increase over time, whereas
CYP2C8 activity decreases over time (68, 141). Importantly, the
activity for some CYP450 enzymes involved in drug metabolism
is reported to be 10-fold to 1,000-fold higher than in 2D
monolayers at day 21 of culture (141). There is still an initial drop
in activity for a number of CYP450 enzymes in PHH spheroids,
however, the loss of activity is at a much slower rate than in
2D monolayers and will often show some level of recovery over
time (68, 71, 141). PHH spheroids also develop bile canaliculi-like
networks and show a protein profile and ADME profile that more
closely resembles the in-vivo liver than do 2D monolayers (68).
Data suggests that albumin secretion is maintained over time in
PHH spheroids cultured in a perfusion bioreactor, whereas urea
secretion decreases over time until plateauing (142).
Due to their metabolic capabilities and the ability to culture
them for longer, PHH spheroids have proven to be a useful
model to study xenobiotic metabolism and identify human-
specific metabolites (143). When incubated with several drugs,
they were shown to be capable of generating the majority of
metabolites detected in vivo for these drugs, indicating activity
for a number of important CYP450 enzymes, UGTs, and SULTs.
Unfortunately, the model was unable to detect NAPQI, the
toxic metabolite of acetaminophen, which was likely due to low
CYP1A2 and CYP2E1 activity, but this may have been detectable
at higher doses (143), as the concentration of acetaminophen
used (10µM) in this study was much less than the IC50 (i.e.,
TC50) values reported for PHH spheroids, which tend to be
above 320µM (12). Nevertheless, when compared to spheroids
established from other cell types, PHH spheroids are shown
to be the most sensitive to acetaminophen toxicity (12). The
improved metabolic activity for 3D spheroids compared to 2D
monolayers may, at least in part, explain the greater sensitivity
of 3D spheroids to detect known hepatotoxins at concentrations
that are toxicologically relevant in-vivo, including for previously
withdrawn drugs such as fialuridine and troglitazone (68, 71,
144). Thanks to expression of MRP2 and bile-acid-inducible
BSEP and the ability to dose them for longer, PHH spheroids
have also successfully been used to establish a model for detecting
drugs with a cholestatic potential, which shows good sensitivity
and specificity, following a 14 day repeat-dosing regimen (145).
It is, however, worth noting that a HepaRG 3D spheroid model
performed equally well (145). A PHH spheroid model cultured
in defined conditions has also been described and shown to
have relatively good sensitivity and excellent specificity (69 and
100%, respectively) for detecting DILI-positive compounds, in a
model that uses an 80% viability threshold for identifying DILI-
positive compounds and involves a repeat dosing regimen at 1x,
5x, and 20x Cmax (146). A separate study that used a margin of
safety (i.e., IC50/Cmax) threshold for identifying DILI-positive
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compounds showed a sensitivity of 32, 55, and 61% when using a
margin of safety threshold of 10, 30, and 50, respectively, which
corresponded with specificities of 95, 87, and 79% (81).
STEM-CELL-DERIVED HEPATOCYTE-LIKE
CELLS
Human embryonic stem cells (hESCs) and induced pluripotent
stem cells (iPSCs) are pluripotent stem cells that are capable
of self-renewal and generating all cell types in the adult
human body (147). Hence, they provide an unlimited supply
of patient-specific cells that can be used to generate patient-
specific hepatocyte-like cells (HLCs) to study DILI (148, 149).
The first reported protocol for the production of human
hepatocyte-like cells involved the use of hESCs (150). These
were cultured as spheroids at the hESC stage (i.e., producing
an embryoid body), which were then treated with DMSO
and sodium butyrate, and left to spontaneously differentiate
into cells from all 3 germ layers, before selecting for HLCs
(150). The use of hESCs, however, is a contentious area due
to the ethical issues associated with the destruction of an
embryo, which is required to isolate the hESCs (151). Their
application for investigating the mechanistic details of patient-
specific DILI is also limited, as models would be specific for the
undeveloped embryo.
In 2006, Yamanaka et al. identified four factors, Oct3/4,
Klf4, Sox2, and c-Myc, that were capable of reprogramming
mouse fibroblasts into a pluripotent stem cell-like state
(152). The following year, they reported a similar method
to reprogram human fibroblasts to a pluripotent stem cell-
like state that resembled hESCs (153). This would help
overcome the ethical issues associated with hESCs and had
the benefit of being patient-specific and readily available
from easily isolatable cells. Since the original method
described by (150), a number of different protocols have
been described for differentiating pluripotent stem cells to
HLCs with a greater efficiency and a phenotype that more
closely resembles in-vivo hepatocytes. This includes the use
of growth factors and small molecules (61, 154, 155), small
molecules alone (59, 156), or transcription factors (157).
These protocols aim to recapitulate the developmental
process of hepatogenesis, directing the stem cells to
differentiate into definitive endoderm, hepatoblasts, and
finally hepatocyte-like cells.
Unfortunately, HLCs cultured as 2D monolayers still lack
the maturity of in-vivo hepatocytes, displaying a phenotype that
more closely resembles fetal hepatocytes (65). Due to the benefits
of culturing cell lines and PHH as spheroids, a number of studies
have looked at whether growing HLCs as spheroids can promote
a more mature phenotype. These spheroids have been cultured
at the stem cell stage of differentiation (i.e., producing embryoid
bodies) (109, 158–160) or during the hepatoblast/maturation
stage of differentiation (72, 87, 91, 158, 161).
Data indicates that culturing iPSCs as spheroids can promote
a more efficient differentiation to the definitive endoderm, when
compared to 2D cultures (162). This also seems to translate
to HLCs, with differentiated HLC spheroids showing higher
expression for a number of hepatocyte markers, including
several CYP450 enzymes and GSTA1, with lower expression
of mesenchymal markers (160). A1AT secretion decreased over
time in both 2D and 3D cultures, but the rate at which it
decreased was slower in 3D. Albumin and urea secretion was
comparable over the 18 day study, although it was statistically
significantly higher by day 18 (160). In a separate study, it
was shown that CYP3A4 activity could be maintained in HLC
spheroids for 1 year using a standard maintenance medium,
although its activity and induction tended to peak around day
60 (109). Although albumin levels increased over the 30 day
differentiation period, it was still much less than in human
liver tissue (more than 80-fold lower). Expression of AFP also
increased over these 30 days and was more than 300 times higher
than in human liver, indicating an immature/fetal phenotype
is still present at day 30. Nevertheless, HLCs continued to
mature over time, with AFP secretion decreasing to negligible
levels between days 20 and 90, whereas albumin secretion
increased (109). Interestingly, spheroids in this study developed
a peripheral layer of HLCs with what appears to be a vimentin-
positive mesenchymal core, although this is yet to be fully
characterized (109). The spheroid structure also seems to show
polarity, expressing the apical membrane transporter BSEP
and basolateral membrane transporter MRP1, the latter being
localized to the inner side of the peripheral layer of HLCs.
The number of proliferating cells also decreases over time,
presumably as stem cells and progenitor cells became terminally
differentiated HLCs (109).
Culturing HLCs as spheroids following differentiation or
during the maturation stage can also promote a more mature
hepatocyte phenotype, when compared to 2D monolayers
(72, 91, 158). For example, increased activity for CYP3A4,
1A2, and 2C9, increased expression of UGT1A1, 1A6, MRP2,
and BSEP, and increased secretion of albumin and urea, at
day 11 of culture, when compared to 2D cultures at the
corresponding time point (72). Furthermore, data indicates
that CYP3A4 activity is maintained for at least 75 days in
3D cultures, whereas it is limited to 45 days in 2D cultures
due to prolific cell death (91). Initial seeding density may also
influence the culture morphology and phenotype, as spheroids
formed from low seeding densities display a cyst-like structure
following differentiation, whereas those seeded with a high
number of cells are much more dense (160, 163). Larger
spheroids show greater differentiation efficiency (i.e., higher
expression for mature hepatocyte markers and lower fetal /
biliary markers), and, contrary to that seen with immortalized
/ cancer cell lines, secrete more albumin per cell than smaller
spheroids (123, 163).
Although HLCs offer great potential for investigating patient-
specific toxicities, culturing and differentiating stem cells toHLCs
is no trivial process. Alongside the immature phenotype of HLCs,
the process is also very costly and labor intensive. The benefit
of HLC spheroids for the safety assessment of drugs is still
debatable until a comprehensive evaluation of their predictability
is completed, but they could be important for investigating
patient-specific toxicities.
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CO-CULTURES
Using the hepatocyte as a single cell type to model DILI is,
of course, an over-simplification and many mechanisms of
hepatotoxicity will have a non-parenchymal cell component and
involve multiple cell types. It may, therefore, be necessary to
include these cell types when studying DILI. Indeed, 3D co-
culture models have been established entirely from immortalized
/ cancer-derived cell lines (i.e., HepaRG cells, hTERT-hepatic
stellate cells, and THP-1 monocytes) (82, 118), entirely from
primary human cells (e.g., PHHs, Kupffer cells, stellate cells and
cholangiocytes) (32, 68, 78–81), and entirely from the same iPSC
(i.e., an isogenic model) (85). The addition of Kupffer cells and
stellate cells provides a convenient model to study DILI with
an immune-mediated mechanism of toxicity (78), investigate
the roles of these cell types in drug-induced toxicities (82) and
evaluate the pro-inflammatory and pro-fibrotic potential of drugs
(68, 80). Cocultures that include just PHHs and Kupffer cells have
also been described and used to evaluate the influence of Kupffer
cell activation on a drug’s toxic potential, with data suggesting
that they can exacerbate toxicity for some drugs and be protective
for others (81). Importantly, primary cell co-cultures can remain
viable for 35 days, have inducible CYP450 enzymes, andmaintain
a relatively stable proteomic profile between day 7 and day 35,
thereby allowing for repeat dosing studies to investigate chronic
toxicities (78, 79). Nevertheless, there was a considerable decrease
in expression for a number of phase I–III proteins by day 7, when
compared to freshly thawed mixtures of PHH and NPCs (79).
Notably, SLC22A1, CYP2C8, and CYP2E1 expression decreased
rapidly over time, beingmore than 10-fold less at day 35, whereas,
MRP2, P-gp, and vimentin increased by day 7 and then remained
stable. CYP1A1, 2B6, 2C9, and 2C19 activity decreased over the
35 days, with peaks in activity often detected about day 14 to
day 21 (79). When compared to 2D PHH monolayers treated
for 48 hours, PHH and NPC co-culture spheroids (aka. liver
microtissues) treated for 14 days have greater sensitivity to detect
DILI-positive compounds, with comparable specificity (32).
The addition of non-parenchymal cells does not, however,
guarantee a better model system to study DILI, with data
suggesting that NCPsmay reduce the expression of some CYP450
enzymes (80). Similar findings were seen with co-cultures that
contain HLCs and stellate cells and HLCs and cholangiocytes
(72). These detrimental effects, however, could be due to a
sample dilution effect, resulting from the addition of cells that
do not express these enzymes and proliferate when activated,
causing them to overgrow the HLCs and PHHs in the spheroid
(72, 80). Contrary to these findings, co-culture spheroids that
include HLCs and endothelial cells have higher urea secretion
and CYP450 activity than spheroid cultures comprised of HLCs
alone (72). Furthermore, evidence is gathering to indicate that the
addition of mesenchymal stem cells and endothelial cells can help
improve the maturity of hepatocytes in vitro (i.e., albumin, urea,
CYP450 markers), promoting hepatocyte polarization and 3D
self-organization into structures with endothelial-like networks
(72, 83–85, 164). Data indicates that cell-cell interactions between
these cell types and paracrine signaling from mesenchymal cells
and endothelial cells (i.e., FGF2 and BMP4) is important for this
3D self-organization and maturation (83, 84). After 12 days in
culture, albumin secretion from these tricultures was shown to
be comparable to human adult hepatocytes, although the gene
expression of a number of hepatocyte markers still fell short of
those seen in adult human liver tissue, approaching levels in fetal
liver tissue (83). 3D spheroid co-cultures containing MSCs and
PHHs, which have been grown in perfusion-based bioreactors,
have also shown increased activity for some phase I and II
enzymes, including CYP3A4, when compared to their respective
3D monocultures (77).
Reduced Wnt and TGF-beta signaling may also be important
for hepatocyte maturation in 3D cocultures (159, 165).
Interestingly, the inclusion of isogenic endothelial cells,
compared to a heterogenic primary endothelial cell line, seemed
to be more important than including isogenic mesenchymal
cells, for maturation of hepatocytes, based on gene expression for
several hepatic DMETs and albumin and AFP secretion (165).
However, this may not be the case when using different primary
cell lines or iPSCs and, therefore, needs further investigation.
It is also worth noting, however, that the addition of NPCs
to PHHs grown as 2D monolayers can also increase activity
for a number of CYP450 enzymes, although this only becomes
apparent after 8 to 9 days in culture and SULT activity rapidly
decreases over this period (166). Interestingly, these PHH-
NPC 2D cocultures displayed less sensitivity and comparable
specificity, when compared to PHH 2D monocultures, although
the specificity for the cocultures increased with repeat exposures
over 7 and 14 days (167), again highlighting the importance of
exposure time and culture duration on the cells phenotype and
sensitivity to known hepatotoxins (167).
ORGANOIDS
Organoids derive from stem cells that have undergone chemically
induced organogenesis, resulting in a 3D heterogeneous
collection of cells that can recreate the organ microanatomy,
containing phenotypically similar cells. Liver organoids can
derive from liver progenitor cells (i.e., adult stem cell-like
cells found in the liver) or pluripotent stem cells (i.e., ESCs
or iPSCs). Organoid derivation from liver tissue involves the
isolation of EPCAM + liver progenitor cells (aka. ductal “oval”
cells) from liver resections/biopsies. These are then embedded
into a Matrigel matrix and cultured with a combination of
growth factors (i.e., HGF, EGF, FGF, Wnt, TGFβ, and Rspo1),
causing EPCAM + cells to become activated bipotent liver
progenitor cells that self-organize into a 3D spherical structure
(92). The resulting 3D spherical organoids have a single-
layered EPCAM + epithelial compartment, resembling the
hepatic ductal compartment. Blockade of ductal fate by Notch
inhibition, a potent inducer of ductal morphogenesis (168,
169), in combination with the inhibition of TGF-β signaling,
removal of Rspo1, and addition of dexamethasone and BMP,
facilitates the differentiation of organoids to a hepatocyte fate
(92). These hepatic organoids have higher expression levels
for several hepatocyte markers [cytochromes, albumin, or α-1-
antitrypsin (A1AT)] and improved hepatic function (i.e., albumin
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production, cytochrome activity and bile acid production in
vitro) (92). Organoids have also been developed without selecting
for EpCAM + cells, from fetal liver tissue (94) or directly from
cryopreserved PHHs (93, 94). Whether this is due to a small
population of EPCAM + progenitor cells that remain after PHH
isolation or dedifferentiation of PHHs to bipotent progenitor
cells remains unclear.
Adult stem cell (ASC) derived organoids (i.e., from EpCAM
+ liver cell isolation) represent an attractive platform to model
DILI, as they possess metabolically active hepatocyte-like cells
that retain the genotypic and some of the phenotypic signatures
of the original tissue, enabling the development of patient-
specific models in vitro (92). Self-organization into structures
that contain a central lumen also permits the diffusion of gases,
such as O2 and CO2, nutrients, and metabolites, which may help
to prevent the formation of a hypoxic or necrotic core. The
requirement of surgical resections of healthy and/ or diseased
tissue, however, can make it difficult to source the ASCs and
brings about complex ethical issues. The use of iPSCs to generate
organoids/liver bud organoids may help overcome these issues
and offers a potentially unlimited supply of patient-specific cells.
Similar to ASC-derived organoids, iPSC-derived hepatocyte-
like cells can retain certain phenotypic features of the original
donor tissue, enabling the development of disease models (170).
The first example of a human liver bud organoid derived
from iPSCs was described in 2013, and included iPSC-derived
hepatocyte-like cells, human umbilical vein endothelial cells
(HUVECs), and mesenchymal stem cells (83). Including an
endothelial and mesenchymal component into the model has
the advantage of being able to investigate toxicities that involve
multiple cell types. However, the use of genetically different cells
can limit the application of the model. For this reason, they went
on to establish a liver bud organoid that contained hepatocyte-
like cells, endothelial cells, and mesenchymal cells, all derived
from the same iPSC clone (85).
When comparing organoids produced from fetal and adult
hepatocytes, fetal-derived hepatic organoids had less CYP3A4
activity than adult-derived hepatic organoids and PHHs, and
also secreted more AFP, indicating, as one might expect, a more
immature phenotype (94). However, AFP secretion did decrease
over time, as the spheroids matured. Secretion of A1AT was
lower than PHHs for both adult and fetal-derived organoids, but
albumin secretion was comparable across them all (94).
Although morphologically similar, transcriptomic analysis
of ASC-derived and ESC-derived hepatic organoids indicates
differential expression for a number of genes, with the former
showing up-regulation for genes associated with Wnt signaling,
and the latter showing up-regulation for genes involved in
liver development (171). When compared to 2D monolayers,
embryonic stem cell-derived organoids display a more mature
phenotype, based on several hepatocyte markers. However, they
still fail to show the maturity seen with PHHs. Data indicates
that hepatic organoids produced from fetal hepatocytes, adult
hepatocytes, and pluripotent stem cells are capable of glycogen
metabolism, LDL metabolism, and develop bile canaliculi-like
structures (94, 171, 172). The addition of human fetal liver
mesenchymal cells, which resemble stellate-like cells, can also
promote maturation of ESC-derived hepatic organoids further
in a co-culture model that could recapitulate the fibrotic
pathogenesis associated with high ethanol exposure and thus
alcoholic liver disease (171). It is also possible to generate
cholangiocyte organoids, using the appropriate conditions (171).
Hepatobiliary organoids, which are derived from iPSCs and
contain both hepatocyte-like and cholangiocyte-like cells, have
also been described in the literature (173).
Organoids derived from human fetal liver tissue have been
maintained for at least 11 months, but the expansion time
may vary depending on the starting tissue (i.e., fetal liver
tissue or adult primary hepatocytes) (94). Patient-derived tumor
organoids are also capable of recapitulating the features of
the original tumor in vitro, providing a model for identifying
oncogenic mutations with prognostic value in liver cancer
and identifying potential drug targets, enabling a personalized
medicine approach and a patient-specific model for testing a
drug’s efficacy and toxicity (174, 175).
Although liver organoids from ASCs and iPSCs provide an
attractive platform to model DILI, there are still some hurdles to
overcome. They are relatively labor intensive (e.g., isolating oval
cells, maintaining stem cells, differentiating, characterizing, etc.),
very expensive to grow, and the efficiency of organoid production
is often low. The use of slightly different growth conditions and
media can also result in low reproducibility for human organoid
data in the literature.
PERFUSION-BASED SYSTEMS AND
MICROFLUIDIC DEVICES
Perfusion-based in-vitro models have several benefits; (1) they
can recapitulate vascular perfusion in the human body, (2)
shear stresses and tension forces inflicted on the cell membranes
are included in the model, enabling mechano-transduction, (3)
connecting different cell types or organs under flow allows the
transport of metabolites, cytokines, and signaling molecules,
thereby considering the influence of different cell types or organs
when assessing drug-induced toxicities, (4) pharmacokinetic
studies are possible with the correct setup, (5) open-loop circuits
enable repeat dosing experiments, (6) flow systemswith air-liquid
interfaces provide a model system to study permeability and
barrier function, and (7) concentration gradients for nutrients,
signalingmolecules, andO2 can be setup across the system, which
may help to establish liver models capable of modeling liver
zonation in vitro, resembling that seen in the in-vivo setting. The
use of automated stirred-tank bioreactors also provides a method
to promote spheroid formation, whilst offering precise control
of the culture parameters, which may help to prolong culture
duration, enabling repeat-dosing and chronic toxicity studies
(77, 142).
Data indicates that the flow rate and thus the shear stresses
inflicted on the cell membrane can influence the expression
of CYP450 enzymes, with higher flow rates promoting greater
CYP1A2 activity in 2D and the opposite trend being seen in
3D (76). Similar findings for the effect of flow on CYP1A2 was
also seen at the mRNA level (75). They also showed increased
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expression of CYP3A4 mRNA when exposed to flow (75).
Another study indicates that albumin secretion, urea secretion,
and CYP1A2 activity is increased when HepG2/C3A cells are
exposed to flow; however, this did not correlate with the CYP1A2
protein expression data (118). The addition of flow also caused
reduced expression of CYP2E1 and had no effect on CYP3A4
activity (118). A separate study showed that the addition of flow
to PHH cultures had no effect on the activity for six CYP450
enzymes, but did cause a non-statistically significant increase
in UGT and SULT activity (166). Nevertheless, the addition of
flow to PHH/NPC cocultures could promote higher CYP450
activity after 24 hour in culture, when compared to cocultures not
exposed to flow, with CYP3A4 and CYP2D6 activity increasing
and decreasing over time, respectively (166). Comparing flow-
based studies, however, can often be made difficult due to the
use of different cell types, different flow rates / shear stresses,
and different flow-based platforms (e.g., vessels and materials,
etc.). The coefficient of variation can also be very large for
some DMETs with some flow systems, which can be problematic
when trying to develop a reproducible model (75). Although
perfusion-based systems provide a convenient platform to model
a number of biological barriers (176, 177), the benefit for liver
models remains to be determined. Their greatest potential may
come from their ability to develop multi-organ platforms to
investigate the effect of one cell type or organ on the toxicity
of another, in particular how hepatic metabolism contributes to
drug-induced toxicities at other organs. For example, a heart-
liver flow-based system has previously been used to study the
role of hepatic metabolism in drug-induced cardiotoxicity (178).
Perfusion-based models may also be useful for promoting the
generation of mature hepatocyte organoids or HLCs derived
from stem cells, as mechano-transduction and chemical gradients
play a key role in developmental processes (179).
There are still many challenges with perfusion-based systems
that must be considered, including non-specific binding in
tubing and plates, especially microfluidic platforms that use
PDMS (180, 181). For example, drugs with a partition coefficient
<295 (i.e., LogP < 2.47 show minimal absorption (<10%)
with PDMS, whereas those with LogP > 2.62 show extensive
absorption (>90%) (181). Extensive testing of the flow-based
system is, therefore, essential for robust and reproducible
research. Bubbles and evaporation can also be particularly
problematic for microfluidic devices due to the narrow channel
design and use of small volumes (180, 182, 183). For more
details on microfluidic devices, the reader is directed to several
comprehensive reviews (183–185).
DISCUSSION AND FUTURE
PERSPECTIVES
In vitro liver models provide a valuable tool to evaluate a
drug’s toxic potential and investigate the mechanistic details
of DILI. Conventionally, this has involved culturing primary
human hepatocytes or immortalized/cancer-derived cell lines as
2D monolayers. However, the cells used in these models will
often be phenotypically different from in-vivo hepatocytes (i.e.,
TABLE 3 | Overview of findings for 3D PHH spheroids and comparisons with 2D
PHH monolayers and sandwich cultures.
Finding (3D vs. 2D) Reference(s)
Ammonia metabolism/urea secretion is higher in spheroids (73)
Gene expression is higher and/or maintained for longer for a
number of phase I proteins in spheroid cultures
(68, 141, 144)
Activity for CYP450 enzymes involved in xenobiotic
metabolism is higher and /or maintained for longer in
spheroids
(71, 73, 89, 141)
Protein expression for a number of phase I, II, and III proteins
is maintained for longer in spheroids
(71)
CYP1A2, 2C9, 2C19, and 3A4 more inducible to known
pharmacological inducers
(89)
Gene expression for phase II and III proteins, nuclear
receptors, and hepatocyte markers is higher and/or
maintained for longer in spheroids
(141, 144)
GSTP1 gene expression lower in spheroids (141)
CYP4A11 and SLC27A5 expression lost more rapidly in
spheroids
(71)
Lower protein expression for some basolateral transporters in
spheroids
(71)
Proteomic and metabolite profile is more stable in 3D cultures
over time
(71, 141)
Spheroid cultures have greater sensitivity to detect toxicity for
known hepatotoxic compounds at toxicologically relevant
concentrations
(71, 73, 81)
Spheroid cultures show greater recovery from the
dedifferentiation process associated with in-vitro culture,
when considering gene expression
(74)
cancer-derived cell lines), or rapidly dedifferentiate, becoming
metabolically incompetent, when cultured in vitro (i.e., PHH).
This hinders their ability to investigate metabolism-dependent
toxicities and limits their application for detecting DILI-positive
compounds, particularly over chronic and repeat dose time
courses that aremore emulative of in-vivomanifestations of DILI.
There is now a large amount of evidence to indicate that the
phenotype of these cells can become more comparable to in-
vivo hepatocytes and the dedifferentiation process delayed, when
culturing the same cells in 3D. This includes higher albumin and
urea secretion, and higher expression and activity for a number of
important phase I-III proteins involved in xenobiotic metabolism
(Tables 2–4). These beneficial effects may be due, at least in part,
to the development of extensive cell-to-cell interactions, which,
along with changes to the cell’s shape and the mechanical forces
inflicted on cells (e.g., tension), can influence cell signaling and
cell fate (74, 186, 187). The ability to run three-dimensional
cultures for longer may also be important for producing a more
mature phenotype, with some cell types only showing increased
expression for some metabolic proteins after 7–14 days (67).
This also permits repeat dosing regimens, enabling the study
and detection of chronic drug-induced toxicities (47, 145). The
extra dimension to 3D models, however, tends to make them less
reproducible than the same cells cultured in 2D (90).
Cell selection is an important consideration and should
be based on the parameter under investigation. Immortalized
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TABLE 4 | Overview of 3D liver models that utilize hepatocyte-like cells (HLCs)
and their phenotypic characteristics.
Finding (3D vs. 2D) Reference(s)
Higher CYP3A4 expression in spheroids (87, 163)
Higher CYP2C9 expression in spheroids (87)
CYP2C9 and 3A4 expression is more inducible in spheroids (87)
Greater albumin secretion in spheroids (163)
Expression of fetal/immature hepatocyte markers (e.g., AFP and
CYP3A7) are lower in spheroids
(72, 91, 163)
Gene expression for some UGTs and canalicular transporters is
higher in 3D cultures
(72, 91)
Higher CYP1A2, 2C9, and 3A4 activity after 11 days in spheroids (72, 91)
2D and 3D cultures both capable of lipid and glycogen storage (91)
and cancer cell lines have the advantage of being well-
characterized, reproducible, and robust. When compared to
PHHs, the current gold standard, they also do not require
invasive procedures to source and offer a potentially unlimited
supply of cells. However, due to them being continually
proliferating cells, 3D cultures can develop a hypoxic and
necrotic core, which may limit how long they can remain in
culture, although the 3D format still shows extended longevity
over their 2D counterparts. This issue becomes less of a problem
when using HepaRG cells, which can be differentiated to a
mixed population of non-proliferating, terminally differentiated
hepatocyte-like cells and biliary epithelial-like cells, prior to
spheroid formation, enabling spheroid size to remain stable
over time. Furthermore, they have metabolic capabilities (i.e.,
expression and activity of phase I-III proteins) that are
approaching those seen in PHHs, which also improves when
cultured as spheroids. They, therefore, offer a suitable cell
to study DILI, but the extended time requirement necessary
for their differentiation can limit their high throughput
capabilities. The lack of genetic variation in cell lines can
also prevent the detection of patient-specific toxicities resulting
from gene polymorphisms, although this can be investigated
using genetic manipulation, offering a convenient test system
to investigate the findings from Genome-wide association
studies (GWAS).
When it comes to investigating patient-specific toxicities with
a genetic basis, HLC spheroids and organoids may provide an
invaluable tool. Unfortunately, similar to PHHs, the production
of organoids from isolated liver progenitor cells (aka. oval
cells) requires liver resections. Nevertheless, there are a number
of examples of organoids/organoid-like structures developed
from iPSC-derived HLCs. These can provide an unlimited
supply of patient-specific hepatocytes to study DILI, from easily
isolatable cells (i.e., peripheral blood mononuclear cells—PBMCs
or fibroblasts). They also have better metabolic capabilities
than many cancer-derived and immortalized cell lines. The
immature phenotype of HLCs, however, limits their application,
and although growing them in 3D can promote a more mature
phenotype, they still lack the maturity and metabolic capabilities
of freshly isolated PHHs.
The benefit of adding different cell types to 3D hepatocyte
cultures seems to be dependent on the cell types added.
Data suggests that co-cultures with endothelial cells and
mesenchymal cells may be the most suitable combination to
promote a mature hepatocyte phenotype. However, the benefit
of each non-parenchymal cell (NPC) type may be dependent
on the mechanistic details of interest, as a number of drug-
induced toxicities will have an immune-mediated response,
which could initiate hepatotoxicity or cause a secondary
insult (i.e., in response to the secretion of pro-inflammatory
cytokines). Nevertheless, having multiple cell types in a model
(e.g., organoids and spheroids containing multiple cell types)
can make the data more difficult to interpret. Selecting the
correct ratio of cells in coculture models is also an important
consideration, as data suggests that this can influence the
hepatocyte phenotype (118).
Based on a number of parameters for hepatocyte function
and maturation, three-dimensional culture systems have a
number of advantages over 2D monolayers; however, many
of the established assays and analytical techniques are for 2D
methods. Imaging and high throughput techniques can be
particularly challenging for 3D cultures. Hence, the rate at
which the field of 3D biology can progress is dependent on
the analytical techniques, reagents, and culture plates available
for 3D platforms. Although these are becoming more widely
available, they tend to be more expensive than the 2D monolayer
equivalents. However, the use of commercially available ultra-
low adhesion plates can help increase the reproducibility of
data, and there are a number of commercially available assay
kits, optimized for use with 3D cultures (e.g., more sensitive
to account for fewer cells in 3D spheroids compared to 2D
monolayers). Attempts are also being made to optimize suitable
microscopy techniques to assess toxicity using 3D cultures
(188), although, based on their data, it is unclear whether HLC
spheroids provide any advantage over 2D HLC monolayers for
detecting DILI-positive compounds (188). However, the method
of assessment could have a significant effect on the outcome.
Protocols for producing high resolution images of 3D cultures
using fluorescence microscopy have also been described (189).
In the future, perfusion-based systems may play an important
role in helping to reveal the mechanistic details for drug-
induced toxicities involving multiple organs. However, these
systems still require a large amount of optimisation to
culture cells from different organs in the same system for
an extended time. Identifying the optimal flow rates to
achieve physiologically relevant hepatocyte function can also
be challenging and can change depending on whether cells are
cultured as spheroids or monolayers. The reproducibility of
these systems is also yet to be determined. The development
of new technologies (e.g., nano sensors) that are biologically
safe and capable of measuring parameters throughout these
systems and at the cell membrane (e.g., [O2], shear stresses,
etc.) may help in characterizing these models and understanding
how these parameters influence biological processes and
hepatocyte function. Consequently, many of the current flow
systems have to rely on computational modeling to achieve
this (190).
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The metabolic capabilities of different cell types and models
are extensively covered in this review and are an important
consideration when establishing models to investigate and
detect metabolism-dependent toxicities. However, there have
been relatively few studies that have comprehensively evaluated
a model’s predictive capabilities for detecting DILI-positive
compounds, with most using very small test sets, and in some
instances only having two or less DILI-negative compounds.
Although discussed throughout this review, a comprehensive
review of the predictive capabilities of different 3D spheroid
models can be found in a separate review (12). At current,
PHH spheroids and PHH coculture spheroids have been the
most extensively evaluated spheroid systems for their predictive
capabilities (32, 81, 146). Importantly, the quality of a model
for detecting DILI-positive compounds is dependent on both
its sensitivity and specificity. Moreover, a model that has high
sensitivity and low specificity offers little practical application
in drug discovery and development, potentially leading to the
unnecessary attrition of drugs and testing on animals. Likewise,
in-vitro models with high specificity and low sensitivity may
be indicative of being mechanistically inadequate to detect the
toxicity of interest.
Although there are now a number of methods that can
increase the complexity of 2D in-vitro models, it is important to
understand their limitations and remember that an increase in
complexity does not always translate to a better model. Moreover,
the ideal model should be able to answer the question(s) of
interest, whilst also being as simple as possible.
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